Zeo ScientifiX (ZEOX) Liabilities and Shareholders Equity (2012 - 2026)
Zeo ScientifiX (ZEOX) posted quarterly Liabilities and Shareholders Equity of $3.9 million for Q2 2026, up 170.8% year-over-year from $1.4 million in Q2 2025, and up 51.15% quarter-over-quarter from $2.6 million in Q1 2026.
Zeo ScientifiX (ZEOX) Liabilities and Shareholders Equity (2012 - 2026) Analysis & Trends
Zeo ScientifiX's Liabilities and Shareholders Equity history runs 15 years deep, the most recent figure standing at $3.9 million for Q2 2026.
- In Q2 2026, Liabilities and Shareholders Equity rose 170.8% year-over-year to $3.9 million; the TTM figure through Apr 2026 stood at $9.6 million (up 40.69% YoY), while the FY2025 annual figure was $1.5 million, down 7.06% from the prior year.
- Liabilities and Shareholders Equity for Q2 2026 stood at $3.9 million, up from $2.6 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $6.2 million in Q4 2022, with the low at $1.4 million in Q2 2025.
- The 5-year median for Liabilities and Shareholders Equity is $2.3 million (2024), against an average of $2.6 million.
- The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity jumped 220.79% in 2022, then slumped 55.13% in 2023.
- Zeo ScientifiX's Liabilities and Shareholders Equity stood at $6.2 million in 2022, then plunged by 55.13% to $2.8 million in 2023, then tumbled by 40.94% to $1.6 million in 2024, then declined by 7.06% to $1.5 million in 2025, then soared by 154.49% to $3.9 million in 2026.
- Business Quant data shows ZEOX's Liabilities and Shareholders Equity at $3.9 million in Q2 2026, $2.6 million in Q1 2026, and $1.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Zeo ScientifiX | 10.51 Mn | 8.67 Mn | 2.06 Mn | 3.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 3.89 Mn |
| Jan 31, 2026 | 2.57 Mn |
| Oct 31, 2025 | 1.53 Mn |
| Jul 31, 2025 | 1.65 Mn |
| Apr 30, 2025 | 1.44 Mn |
| Jan 31, 2025 | 1.55 Mn |
| Oct 31, 2024 | 1.64 Mn |
| Jul 31, 2024 | 2.22 Mn |
| Apr 30, 2024 | 1.93 Mn |
| Jan 31, 2024 | 2.43 Mn |
| Oct 31, 2023 | 2.78 Mn |
| Jul 31, 2023 | 2.46 Mn |
| Apr 30, 2023 | 3.33 Mn |
| Jan 31, 2023 | 4.32 Mn |
| Oct 31, 2022 | 6.20 Mn |
| Jul 31, 2022 | 2.56 Mn |
| Apr 30, 2022 | 2.21 Mn |
| Jan 31, 2022 | 2.08 Mn |
| Oct 31, 2021 | 1.93 Mn |
| Jul 31, 2021 | 1.72 Mn |